Literature DB >> 24940099

Treatment outcomes for male breast cancer: a single-centre retrospective case-control study.

M Rushton1, A Kwong1, H Visram1, N Graham2, W Petrcich3, S Dent2.   

Abstract

BACKGROUND: Male breast cancer (bc) is a rare disease, and the availability of information on treatment outcomes is limited compared with that for female bc. The objective of the present study was to compare disease-free (dfs) and overall survival (os) for men compared with women having early-stage bc.
METHODS: This retrospective case-control study compared men and women treated for stage 0-iiib bc at a single institution between 1981 and 2009. Matching was based on age at diagnosis, year of diagnosis, and stage. Treatment, recurrence, and survival data were collected. Kaplan-Meier analysis was used to calculate os and dfs.
RESULTS: For the 144 eligible patients (72 men, 72 women), median age at diagnosis was 66.5 years. Treatments included mastectomy (72 men, 38 women), radiation (29 men, 44 women), chemotherapy (23 men, 20 women), and endocrine therapy (57 men, 57 women). Mean dfs was 127 months for women compared with 93 months for men (p = 0.62). Mean os was 117 months for women compared with 124 months for men (p = 0.35). In multivariate analysis, the only parameter that affected both dfs and os was stage at diagnosis.
CONCLUSIONS: This case-control study is one of the largest to report treatment outcomes in early-stage male bc patients treated in a non-trial setting. Male patients received systemic therapy that was comparable to that received by their female counterparts, and they had similar os and dfs. These results add to current evidence from population studies that male sex is not a poor prognostic factor in early-stage breast cancer.

Entities:  

Keywords:  Male breast cancer; outcomes comparison; treatment

Year:  2014        PMID: 24940099      PMCID: PMC4059803          DOI: 10.3747/co.21.1730

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  24 in total

Review 1.  Some aspects of the endocrine profile and management of hormone-dependent male breast cancer.

Authors:  Nikolay V Dimitrov; Philomena Colucci; Sunil Nagpal
Journal:  Oncologist       Date:  2007-07

Review 2.  Male breast cancer: risk factors, diagnosis, and management (Review).

Authors:  Katherine A Johansen Taber; Lee R Morisy; Albert J Osbahr; Barry D Dickinson
Journal:  Oncol Rep       Date:  2010-11       Impact factor: 3.906

3.  Endocrine therapy for male breast cancer: rates of toxicity and adherence.

Authors:  H Visram; F Kanji; S F Dent
Journal:  Curr Oncol       Date:  2010-10       Impact factor: 3.677

4.  Molecular subtyping of male breast cancer by immunohistochemistry.

Authors:  Robert Kornegoor; Anoek H J Verschuur-Maes; Horst Buerger; Marieke C H Hogenes; Peter C de Bruin; Joost J Oudejans; Petra van der Groep; Bernd Hinrichs; Paul J van Diest
Journal:  Mod Pathol       Date:  2011-11-04       Impact factor: 7.842

5.  Male breast cancer: a population-based comparison with female breast cancer.

Authors:  William F Anderson; Ismail Jatoi; Julia Tse; Philip S Rosenberg
Journal:  J Clin Oncol       Date:  2009-12-07       Impact factor: 44.544

Review 6.  Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.

Authors:  Eitan Amir; Bostjan Seruga; Saroj Niraula; Lindsay Carlsson; Alberto Ocaña
Journal:  J Natl Cancer Inst       Date:  2011-07-09       Impact factor: 13.506

7.  Steroid hormone receptor expression in male breast cancer.

Authors:  C E Murphy; P J Carder; M R J Lansdown; V Speirs
Journal:  Eur J Surg Oncol       Date:  2005-11-02       Impact factor: 4.424

8.  Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients.

Authors:  Holm Eggemann; Atanas Ignatov; Bobbie J Smith; Udo Altmann; Gunter von Minckwitz; Freidrich W Röhl; Mark Jahn; Serban-Dan Costa
Journal:  Breast Cancer Res Treat       Date:  2012-12-09       Impact factor: 4.872

9.  Men with breast cancer have same disease-specific and event-free survival as women.

Authors:  Frédéric Marchal; Magalie Salou; Christian Marchal; Anne Lesur; Emmanuel Desandes
Journal:  Ann Surg Oncol       Date:  2009-01-30       Impact factor: 5.344

10.  Linkage to BRCA2 region in hereditary male breast cancer.

Authors:  S Thorlacius; L Tryggvadottir; G H Olafsdottir; J G Jonasson; H M Ogmundsdottir; H Tulinius; J E Eyfjord
Journal:  Lancet       Date:  1995-08-26       Impact factor: 79.321

View more
  3 in total

1.  Male Breast Cancer Prognostic Factors Versus Female Counterparts with Propensity Scores and Matched-Pair Analysis.

Authors:  Edward Yu; Larry Stitt; Olga Vujovic; Kurian Joseph; Avi Assouline; Jawaid Younus; Francisco Perera; Patricia Tai
Journal:  Cureus       Date:  2015-10-16

2.  Adjuvant Radiation Therapy for Male Breast Cancer-A Rare Indication?

Authors:  Tobias Forster; Clara Köhler; Rami El Shafie; Fabian Weykamp; Laila König; Nathalie Arians; Sebastian Adeberg; Laura Michel; Katharina Smetanay; Michael Golatta; Christof Sohn; Jörg Heil; Andreas Schneeweiss; Jürgen Debus; Juliane Hörner-Rieber
Journal:  Cancers (Basel)       Date:  2020-12-04       Impact factor: 6.639

3.  The Unknown microRNA Expression of Male Breast Cancer. Similarities and Differences with Female Ductal Carcinoma. Their Role as Tumor Biomarker.

Authors:  Maria J Merino; Sara Gil; Carmen Garcia Macias; Karlena Lara
Journal:  J Cancer       Date:  2018-01-01       Impact factor: 4.207

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.